All Studies Meta Analysis Recent:

Controlled randomized clinical trial on using Ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq

Hashim et al., Iraqi Journal of Medical Science, 19:1, NCT04591600

Oct 2020

Post
Facebook

Source PDF All Meta

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020

^*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.

Lower risk for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,000+ studies for 60+ treatments. c19ivm.org

RCT 70 ivermectin+doxycycline patients and 70 control patients showing reduced time to recovery and reduced mortality with treatment. Earlier treatment was more successful. For ethical reasons, critical patients were all in the treatment group. NCT04591600 (history).

This is the 7th of 49 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000038.

This is the 14th of 102 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 560 quintillion).

Important missing comments or errors? Let us know.

risk of death, 91.7% lower, RR 0.08, p = 0.03, treatment 0 of 59 (0.0%), control 6 of 70 (8.6%), NNT 12, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), excluding non-randomized critical patients, primary outcome.

risk of death, 67.1% lower, RR 0.33, p = 0.16, treatment 2 of 70 (2.9%), control 6 of 70 (8.6%), NNT 18, odds ratio converted to relative risk, including critical patients that were always allocated to treatment.

risk of progression, 83.1% lower, RR 0.17, p = 0.07, treatment 1 of 59 (1.7%), control 7 of 70 (10.0%), NNT 12, excluding non-randomized critical patients.

risk of progression, 57.4% lower, RR 0.43, p = 0.20, treatment 3 of 70 (4.3%), control 7 of 70 (10.0%), NNT 18, odds ratio converted to relative risk, including critical patients that were always allocated to treatment.

recovery time, 40.7% lower, relative time 0.59, p < 0.001, treatment 70, control 70.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Hashim et al., 26 Oct 2020, Single Blind Randomized Controlled Trial, Iraq, peer-reviewed, 7 authors, study period 1 July, 2020 - 14 October, 2020, dosage 200μg/kg days 1-2, some patients received a third dose on day 8, this trial uses multiple treatments in the treatment arm (combined with doxycycline) - results of individual treatments may vary, trial NCT04591600 (history).

This Paper Ivermectin All

Controlled Randomized Clinical Trial on Using Ivermectin with Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq

Hashim A Hashim, MD Mohammed F Maulood, MD Chasib L Ali, Anwar Rasheed, MSc Dhurgham F Fatak, BSc Khulood K Kabah, BSc Ahmed S Abdulamir

Iraqi Journal of Medical Sciences, doi:10.22578/ijms.19.1.14

COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try repurposed old drugs on COVID-19. Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200 µg/kg PO of Ivermectin per day for 2-3 days along with 100 mg PO doxycycline twice per day for 5-10 days plus standard therapy; the second arm is 70 COVID-19 patients (48 mild-moderate and 22 severe and zero critical patients) on standard therapy, which is (vitamin C, D, and zinc, azithromycin, dexamethasone and oxygen supply if needed). The time to recovery, the progression of the disease, and the mortality rate were the outcome-assessing parameters. Among all patients and among severe patients, 3/70 (4.28%) and 1/11 (9%), respectively progressed to a more advanced stage of the disease in the Ivermectin-Doxycycline group versus 7/70 (10%) and 7/22 (31.81%), respectively in the control group (P>0.05). The mortality rate was 0/48 (0%), 0/11 (0%), and 2/11 (18.2%) in mild-moderate, severe, and critical COVID-19 patients, respectively in Ivermectin-Doxycycline group versus 0/48 (0%), and 6/22 (27.27%) in mild-moderate and severe COVID-19 patients, respectively in standard therapy group (p=0.052). Moreover, the mean time to recovery was 6.34, 20.27, and 24.13 days in mild-moderate, severe, and critical COVID-19 patients, respectively in Ivermectin-Doxycycline group versus 13.66 and 24.25 days in mild-moderate and severe COVID-19 patients, respectively in standard therapy group (P<0.01). It is concluded that Ivermectin with doxycycline reduced the time to recovery, the percentage of patients progress to more advanced stage of disease, and reduced mortality rate in severe patients from 22.72% to 0%.

Author contribution Dr. Hashim and Dr. Maulood applied the intervention on patients and collected data. Dr. Abdulamir, Dr. Ali, Rasheed, Fatak, and Kabah designed the clinical trial and the study. Dr. Ahmed S. Abdulamir wrote the manuscript. Conflict of interest Authors confirm that there is no conflict of interest concerning this research and the written manuscript.

References

Abdulamir, Hafidh, The possible immunological pathways for the variable immunopathogenesis of COVID-19 infections among healthy adults, elderly and children, Electron J Gen Med, doi:10.29333/ejgm/7850

Ali, Alfarouk, Reshkin, Doxycycline as potential anti-cancer agent, Anticancer Agents Med Chem, doi:10.2174/1871520617666170213111951

Ali, Hanif, Haider, Treatment Options for COVID-19: A Review, Front Med, doi:10.3389/fmed.2020.00480

Bick, Carroll, Gao, Expression of the zinc-finger antiviral protein inhibits alphavirus replication, J Virol, doi:10.1128/jvi.77.21.11555-11562.2003

Caly, Druce, Catton, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787

Carvallo, Hirsch, Farinella, Safety and efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19, medRxiv, doi:10.1101/2020.09.10.20191619

Dhama, Khan, Tiwari, Coronavirus Disease 2019-COVID-19, Clin Microbiol Rev, doi:10.1128/CMR.00028-20

Gendrot, Andreani, Jardot, In vitro antiviral activity of Doxycycline against SARS-CoV-2, Molecules, doi:10.3390/molecules25215064

Gorial, Mashhadani, Sayaly, Effectiveness of Ivermectin as add-on therapy in COVID-19 management (Pilot trial), medRxiv, doi:10.1101/2020.07.07.20145979

Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot, doi:10.1038/s41429-020-0336-z

Huang, Garcia-Carreras, Hitchings, A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease, Nat Commun, doi:10.1101/2020.04.14.20065771

Lifschitz, Virkel, Sallovitz, Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle, Vet Parasitol, doi:10.1016/s0304-4017(99)00175-2

Malek, Granwehr, Kontoyiannis, Doxycycline as a potential partner of COVID-19 therapies, IDCases, doi:10.1016/j.idcr.2020.e00864

Mudatsir, Yufika, Nainu, antiviral activity of Ivermectin against SARS-CoV-2: An old-fashioned dog with a new trick-A literature review, Sci. Pharm, doi:10.3390/scipharm88030036

O'connell, Bradley, Abbas, Hydroxychloroquine/Azithromycin therapy and QT prolongation in hospitalized patients with COVID-19, JACC Clin Electrophysiol, doi:10.1016/j.jacep.2020.07.016

Pujadas, Chaudhry, Mcbride, SARS-CoV-2 viral load predicts COVID-19 mortality, Lancet Respir Med, doi:10.1016/S2213-2600(20)30354-4

Rajter, Sherman, Fatteh, Use of Ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The Ivermectin in COVID Nineteen Study, Chest, doi:10.1016/j.chest.2020.10.009

Rasheed, Fatak, Hashim, The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq, Infez Med

Rod, Oviedo-Trespalacios, Cortes-Ramirez, A brief-review of the risk factors for covid-19 severity, Rev Saude Publica, doi:10.11606/s1518-8787.2020054002481

Vargas-Estrada, Gutiérrez, Juarez-Rodríguez, Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats, Arzneimittelforschung, doi:10.1055/s-0031-1296512

Vora, Arora, Behera, White paper on Ivermectin as a potential therapy for COVID-19

Wagstaff, Sivakumaran, Heaton, Ivermectin is a specific inhibitor of importin α/βmediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J, doi:10.1042/BJ20120150

Worldmeter, Coronavirus update

Wu, Wang, Wei, Antiviral activity of doxycycline against vesicular stomatitis virus in vitro

Xu, Han, Liu, Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus, PLoS Negl Trop Dis, doi:10.1371/journal.pntd.0006934

Zavala-Castro, Fredeking, Doxycycline modify the cytokine storm in patients with dengue and dengue hemorrhagic fever, Int J Infect Dis, doi:10.1016/j.ijid.2010.02.1586

Zheng, Tao, Cheng, Efficacy of ivermectin for control of microfilaremia recurring after treatment with diethylcarbamazine. II. Immunologic changes following treatment, Am J Trop Med Hyg

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0